Pfizer’s blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests
Pfizer’s tafamidis arrived in the U.S. in 2019 with a vastly discounted list price over rival transthyretin amyloidosis drugs. But its $ 225,000-a-year tag still seems too much for many heart patients. Previous cost-effectiveness analyses and physicians themselves have warned tafamidis is too pricey—the world’s most expensive medication for cardiovascular disease, to be exact. And now,… Read More »